165 related articles for article (PubMed ID: 35466039)
1. Antipseudomonal treatment decisions during CF exacerbation management.
VanDevanter DR; West NE; Sanders DB; Skalland M; Goss CH; Flume PA; Heltshe SL
J Cyst Fibros; 2022 Sep; 21(5):753-758. PubMed ID: 35466039
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes of Antipseudomonal versus Other Antibiotics among Children with Cystic Fibrosis without
Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Nichols DP; Rosenfeld M; Kronman MP
Ann Am Thorac Soc; 2022 Aug; 19(8):1320-1327. PubMed ID: 35289740
[No Abstract] [Full Text] [Related]
3. Antibiotics and outcomes of CF pulmonary exacerbations in children infected with MRSA and Pseudomonas aeruginosa.
Cogen JD; Hall M; Faino AV; Ambroggio L; Blaschke AJ; Brogan TV; Cotter JM; Gibson RL; Grijalva CG; Hersh AL; Lipsett SC; Shah SS; Shapiro DJ; Neuman MI; Gerber JS
J Cyst Fibros; 2023 Mar; 22(2):313-319. PubMed ID: 35945130
[TBL] [Abstract][Full Text] [Related]
4. Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis.
VanDevanter DR; Heltshe SL; Hilliard JB; Konstan MW
J Cyst Fibros; 2021 Mar; 20(2):257-263. PubMed ID: 32505525
[TBL] [Abstract][Full Text] [Related]
5. Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nichols DP; Rosenfeld M; Gibson RL
Clin Infect Dis; 2021 Nov; 73(9):1589-1596. PubMed ID: 34100912
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.
Thornton CS; Caverly LJ; Kalikin LM; Carmody LA; McClellan S; LeBar W; Sanders DB; West NE; Goss CH; Flume PA; Heltshe SL; VanDevanter DR; LiPuma JJ
Ann Am Thorac Soc; 2024 Apr; 21(4):595-603. PubMed ID: 37963297
[No Abstract] [Full Text] [Related]
7. Association of Intensity of Antipseudomonal Antibiotic Therapy With Risk of Treatment-Emergent Organisms in Children With Cystic Fibrosis and Newly Acquired Pseudomonas Aeruginosa.
Cogen JD; Onchiri FM; Hamblett NM; Gibson RL; Morgan WJ; Rosenfeld M
Clin Infect Dis; 2021 Sep; 73(6):987-993. PubMed ID: 33693586
[TBL] [Abstract][Full Text] [Related]
8. Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response.
Lam JC; Somayaji R; Surette MG; Rabin HR; Parkins MD
BMC Infect Dis; 2015 Mar; 15():145. PubMed ID: 25887462
[TBL] [Abstract][Full Text] [Related]
9. Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.
Millar BC; McCaughan J; Rendall JC; Downey DG; Moore JE
J Clin Pharm Ther; 2018 Feb; 43(1):92-100. PubMed ID: 29293275
[TBL] [Abstract][Full Text] [Related]
10. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
[TBL] [Abstract][Full Text] [Related]
11. Aminoglycoside dosing and monitoring for Pseudomonas aeruginosa during acute pulmonary exacerbations in cystic fibrosis.
Ochs MA; Dillman NO; Caverly LJ; Chaffee VD
Pediatr Pulmonol; 2021 Dec; 56(12):3634-3643. PubMed ID: 33983680
[TBL] [Abstract][Full Text] [Related]
12. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
Banerjee D; Stableforth D
Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
[TBL] [Abstract][Full Text] [Related]
13. Antibiotic duration and changes in FEV
Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
[TBL] [Abstract][Full Text] [Related]
14. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.
Langton Hewer SC; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Sutton L; Clayton D; Arch B; Tanajewski Ł; Berdunov V; Williamson PR
Health Technol Assess; 2021 Nov; 25(65):1-128. PubMed ID: 34806975
[TBL] [Abstract][Full Text] [Related]
15. Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial.
Mayer-Hamblett N; Retsch-Bogart G; Kloster M; Accurso F; Rosenfeld M; Albers G; Black P; Brown P; Cairns A; Davis SD; Graff GR; Kerby GS; Orenstein D; Buckingham R; Ramsey BW;
Am J Respir Crit Care Med; 2018 Nov; 198(9):1177-1187. PubMed ID: 29890086
[TBL] [Abstract][Full Text] [Related]
16. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
[TBL] [Abstract][Full Text] [Related]
17. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
[TBL] [Abstract][Full Text] [Related]
18. The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.
VanDevanter EJ; Heltshe SL; Skalland M; Lechtzin N; Nichols D; Goss CH
J Cyst Fibros; 2021 Nov; 20(6):932-936. PubMed ID: 33685776
[TBL] [Abstract][Full Text] [Related]
19. C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response.
VanDevanter DR; Heltshe SL; Skalland M; West NE; Sanders DB; Goss CH; Flume PA
J Cyst Fibros; 2022 Jul; 21(4):588-593. PubMed ID: 34933824
[TBL] [Abstract][Full Text] [Related]
20. Delafloxacin--A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis.
Millar BC; McCaughan J; Rendall JC; Moore JE
Clin Respir J; 2021 Jan; 15(1):116-120. PubMed ID: 32790958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]